Latest Insider Transactions at Exact Sciences Corp (EXAS)
This section provides a real-time view of insider transactions for Exact Sciences Corp (EXAS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXACT SCIENCES CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXACT SCIENCES CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 25
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,195
-0.55%
|
$315,945
$51.28 P/Share
|
|
Feb 25
2025
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,180
+1.16%
|
-
|
|
Feb 25
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
1,859
-8.4%
|
$94,809
$51.28 P/Share
|
|
Feb 25
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+15.16%
|
-
|
|
Feb 25
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
775
-5.64%
|
$39,525
$51.28 P/Share
|
|
Feb 25
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
1,647
+10.71%
|
-
|
|
Feb 25
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,008
-10.12%
|
$102,408
$51.28 P/Share
|
|
Feb 25
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+16.62%
|
-
|
|
Feb 25
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,859
-2.32%
|
$94,809
$51.28 P/Share
|
|
Feb 25
2025
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+4.69%
|
-
|
|
Feb 20
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
1,531
-11.24%
|
$76,550
$50.48 P/Share
|
|
Feb 20
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
3,324
+19.62%
|
-
|
|
Feb 20
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,214
-2.82%
|
$110,700
$50.48 P/Share
|
|
Feb 20
2025
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+5.76%
|
-
|
|
Feb 20
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-13.3%
|
$121,850
$50.48 P/Share
|
|
Feb 20
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+20.77%
|
-
|
|
Feb 20
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
2,225
-10.9%
|
$111,250
$50.48 P/Share
|
|
Feb 20
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+19.06%
|
-
|
|
Feb 20
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,140
-1.87%
|
$1,057,000
$50.48 P/Share
|
|
Feb 20
2025
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,044
+4.08%
|
-
|
|
Feb 19
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-4.04%
|
$21,217
$49.63 P/Share
|
|
Feb 19
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
865
+7.46%
|
-
|
|
Feb 19
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,107
-1.48%
|
$54,243
$49.63 P/Share
|
|
Feb 19
2025
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+2.92%
|
-
|
|
Feb 19
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
968
-6.68%
|
$47,432
$49.63 P/Share
|
|
Feb 19
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,729
+10.66%
|
-
|
|
Feb 19
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
1,086
-6.51%
|
$53,214
$49.63 P/Share
|
|
Feb 19
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+11.87%
|
-
|
|
Feb 19
2025
|
D Scott Coward |
SELL
Payment of exercise price or tax liability
|
Direct |
667
-1.26%
|
$32,683
$49.63 P/Share
|
|
Feb 19
2025
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+4.08%
|
-
|
|
Feb 19
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,271
-0.3%
|
$160,279
$49.63 P/Share
|
|
Feb 19
2025
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,374
+0.95%
|
-
|
|
Jan 02
2025
|
Kimberly J Popovits |
BUY
Grant, award, or other acquisition
|
Direct |
6,387
+50.0%
|
-
|
|
Nov 13
2024
|
Kevin T Conroy President and CEO |
BUY
Open market or private purchase
|
Direct |
19,500
+1.78%
|
$994,500
$51.35 P/Share
|
|
Oct 08
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
929
-6.79%
|
$65,030
$70.0 P/Share
|
|
Sep 18
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
929
-6.36%
|
$65,030
$70.0 P/Share
|
|
Aug 05
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-8.6%
|
$75,625
$55.77 P/Share
|
|
Aug 05
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
2,712
+14.5%
|
-
|
|
Jun 13
2024
|
Michael J Barber |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+50.0%
|
-
|
|
Jun 13
2024
|
Shacey Petrovic |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+25.49%
|
-
|
|
Jun 13
2024
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+9.8%
|
-
|
|
Jun 13
2024
|
Daniel J Levangie |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+16.08%
|
-
|
|
Jun 13
2024
|
Katherine S Zanotti |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+7.21%
|
-
|
|
Jun 13
2024
|
Paul J Clancy |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+21.27%
|
-
|
|
Jun 13
2024
|
Kathleen Sebelius |
BUY
Grant, award, or other acquisition
|
Direct |
6,889
+17.77%
|
-
|
|
Jun 13
2024
|
James Edward Doyle |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+8.92%
|
-
|
|
May 01
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
1,155
-0.1%
|
$69,300
$60.15 P/Share
|
|
May 01
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
102
-0.7%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
102
-0.14%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
110
-0.82%
|
$6,600
$60.15 P/Share
|